1-3 of 3
Alwyn D'Souza
Close
Sort by
Journal Articles

A Phase 1 Dose Escalation Trial of Third-Generation CD19-Directed CAR T-Cells Incorporating CD28 and Toll-like Receptor 2 (TLR2) Intracellular Domains for Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas (ENABLE)

Robert Weinkove, Philip George, Robert Fyfe, Nathaniel Dasyam, Yasmin Nouri, Tess Ostapowicz, Stefan Mullins, Brigitta Mester, Giulia Giunti, Catherine M. Bollard, Travis Perera, Hayden Jina, Alwyn D'Souza, Le Qin, David S. Ritchie, Chris M.A. Frampton, Rachel Perret, Peng Li, Ian Hermans
Journal: Blood
Blood (2023) 142 (Supplement 1): 890.
https://doi.org/10.1182/blood-2023-178872
Published: 2023
Journal Articles

A  High- Risk Genetic Signature Is Predictive For Poor Outcome In Auto-Transplant Eigible Multiple Myeloma Patients Even With Use Of Novel Agents. A Single Institution Study

Kenneth R. Romeril, FRACP, FRCPA, Huib Buyck, Richard Parfitt, Catherine Wood, Alwyn d'Souza, Robert Weinkove, MA, FRCPath
Journal: Blood
Blood (2013) 122 (21): 5371.
https://doi.org/10.1182/blood.V122.21.5371.5371
Published: 2013
Journal Articles

Pax-5 Demonstrates Residual B-Cells in Bone Marrow Trephines Post Anti-CD20 Immunotherapy.

Alwyn D’Souza, MB, ChB, FRACP, Surender Juneja, MBBS, MD, FRCPA, Melanie Trivett, Dennis Carney, MBBS, FRACP, FRCPA, David Westerman, MBBS, FRACP, FRCPA
Journal: Blood
Blood (2005) 106 (11): 5013.
https://doi.org/10.1182/blood.V106.11.5013.5013
Published: 2005